NCT07214740View on ClinicalTrials.gov

Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
DRUG

APL-2, Pegcetacoplan

Complement (C3) Inhibitor

Sponsors
All Listed Sponsors
lead

Apellis Pharmaceuticals, Inc.

INDUSTRY

NCT07214740 - Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe | Biotech Hunter | Biotech Hunter